ストックスクリーナーアプリを入手
0.3835
0.00%
0.00
前日終値:
$0.3835
開ける：
$0.3993
24時間の取引高:
241.73K
Relative Volume:
0.25
時価総額：
$27.43M
収益：
-
当期純損益:
$-26.92M
株価収益率:
-0.752
EPS:
-0.51
ネットキャッシュフロー:
$-18.92M
1週間 パフォーマンス:
-0.49%
1か月 パフォーマンス:
-11.02%
6か月 パフォーマンス:
-66.36%
1年 パフォーマンス:
-86.87%
1日の値動き範囲:
$0.3701
$0.3993
1週間の範囲:
$0.3611
$0.41
52週間の値動き範囲:
$0.3567
$3.08
Cel-Sci Corp. Stock (CVM) Company Profile
名前
Cel-Sci Corp.
セクター
電話
703-506-9460
住所
8229 Boone Boulevard, Suite 802, Vienna, VA
CVM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
0.3826 | 27.43M | 0 | -26.92M | -18.92M | -0.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.51 | 125.43B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
719.38 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
670.87 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.36 | 35.33B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.28 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-01-13 | 開始されました | H.C. Wainwright | Buy |
| 2015-03-02 | 開始されました | Dawson James | Buy |
Cel-Sci Corp. (CVM) 最新ニュース
CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com - Defense World
Personal Finance - Business Wire
Have A Relaxing Holiday Season - MENAFN.COM
Cantex Mine Development (CVE:CD) Stock Price Up 9.5% – Should You Buy? - Defense World
CEL-SCI (NYSE:CVM) Now Covered by StockNews.com - Defense World
CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer - Yahoo Finance
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
CVM stock touches 52-week low at $0.37 amid sharp annual decline - Investing.com Nigeria
Hanlon Investment Management Inc. Purchases 405 Shares of Microsoft Co. (NASDAQ:MSFT) - Defense World
CEL-SCI Corporation (NYSE:CVM) Announces Completion of $5 Million OfferingOn December 31, 2024, CEL-SCI Corporation, a Colorado corporation, disclosed the successful closure of an offering valued at approximately $5,000,000. The offering involved t - Defense World
Cel-Sci Stock Slips After Public Offering: Retail's Neutral - MSN
CEL-SCI completes $5 million stock offering - Investing.com
CEL-SCI Announces Closing of $5 Million Offering - Yahoo Finance
8 things to know: Big Lots strikes deal to save hundreds of stores - The Business Journals
CVM Stock Hits 52-Week Low at $0.42 Amid Market Challenges - Investing.com Nigeria
SEC Form 424B5 filed by Cel-Sci Corporation - Quantisnow
Why Vincerx Pharma Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket - Benzinga
5 Stocks To Watch Heading Into Monday - MSN
CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday - Benzinga
CEL-SCI Announces Pricing of $5 Million Public Offering - Yahoo Finance
CEL-SCI Announces $5M Public Offering to Advance FDA-Designated Orphan Drug Multikine Cancer Therapy - StockTitan
CEL-SCI announces proposed public offering of common stock - MSN
CEL-SCI announces common stock offering, no amount given - MSN
CVMCel-Sci Corporation Latest Stock News & Market Updates - StockTitan
CEL-SCI Announces Proposed Public Offering of Common Stock - Yahoo Finance
Best Penny Stocks for Today (Charts Updated Daily) - Benzinga
Cancer Stocks in the Spotlight: The Immunotherapy Revolution - Baystreet.ca
CEL-SCI (NYSE:CVM) Trading Down 4.4% – Should You Sell? - Defense World
Have a Relaxing Holiday Season - Baystreet.ca
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector - Baystreet.ca
$258 Billion Market: Why Cancer Immunotherapy Is Transforming Both Care and Portfolios - Baystreet.ca
AAR Droops on Linking with GA - Baystreet.ca
Oaktree Specialty Lending (NASDAQ:OCSL) Stock Rating Upgraded by StockNews.com - Defense World
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stake Boosted by The Manufacturers Life Insurance Company - Defense World
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study - Yahoo Finance
CVM: CRO Selected for Registrational Trial - Research Tree
Cel-Sci stock hits 52-week low at $0.54 amid sharp decline - Investing.com
Cel-Sci Corp (CVM) Stock Behavior Is Not Predictable - Stocks Register
Therapeutic Vaccines Market Size on Track to Surpass USD 140 Billion by 2032 at a 18.2% CAGR | VMR - EIN News
StockNews.com Downgrades CEL-SCI (NYSE:CVM) to Sell - Defense World
Cel-Sci Corp. (CVM) 財務データ
収益
当期純利益
現金流量
EPS
0.93%
1.45%
大文字化:
|
ボリューム (24 時間):